Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal (Q37979273)

26 August 2017

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal (English)

1 reference

26 August 2017

1 reference

6

1 reference

26 August 2017

7

Mark Sculpher

1 reference

26 August 2017

Huiqin Yang

1

1 reference

26 August 2017

Dawn Craig

2

1 reference

26 August 2017

David Epstein

3

1 reference

26 August 2017

Laura Bojke

4

1 reference

26 August 2017

Kate Light

5

1 reference

26 August 2017

Nerys Woolacott

8

1 reference

26 August 2017

1 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

30

1 reference

26 August 2017

4

1 reference

26 August 2017

257-270

1 reference

https://scigraph.springernature.com/pub.10.2165/11595920-000000000-00000

26 August 2017

0 references

cites work

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Prevalence of joint disease in patients with psoriasis: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Psoriatic arthritis: therapeutic principles

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

TNFalpha therapy in psoriatic arthritis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Guideline for anti-TNF-alpha therapy in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11595920-000000000-00000

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2

21 January 2018

1 reference

12 December 2020

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal

1 reference

12 December 2020

Golimumab for the treatment of psoriatic arthritis

1 reference

12 December 2020

Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal

1 reference

12 December 2020

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal

1 reference

12 December 2020

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

1 reference

12 December 2020

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal

1 reference

12 December 2020

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

12 December 2020

The authors' reply to Allen et al.: "A Comment on Boyers et al.: 'eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal'".

1 reference

12 December 2020

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

12 December 2020

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal

1 reference

12 December 2020

10.2165/11595920-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

0 references

1 reference